Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study
Authors' conclusion
We did not find significant differences in mortality or respiratory hospitalization between RA-ILD patients initiating different non-TNFi b/tsDMARDs, though estimates were imprecise, and residual confounding may be present.
Study context
- Population
- Patients fulfilling validated RA-ILD algorithms initiating a non-TNFi b/tsDMARD, national Veterans Affairs (VA) data 2006–2020 (mean age 68.1–69.4 years, 88–92 % male)
- Exposure
- Abatacept, tocilizumab or tofacitinib vs rituximab
- Abataceptn = 150
- Tocilizumabn = 73
- Tofacitinibn = 94
- Outcome
- Composite of:
- Death
- Respiratory-related hospitalization
- Follow-up
- three-year
Methodological detailspropensity score-matched (1:1), active-comparator, new-user, three emulated trials, Cox regression
- Propensity score-matched (1:1)
- Active-comparator
- New-user
- Three emulated trials
- Cox regression
Main finding
As reported in the abstract
three-year
Each group vs rituximabAdjusted hazard ratio (CI)
Abatacept
1.03(0.72–1.47)
Tocilizumab
1.15(0.68–1.93)
Tofacitinib
0.89(0.54–1.46)
Observational data: associations, not effects.
Further findings
Composite outcome at one-year follow-up; subgroup and sensitivity analyses
- Secondary, subgroup, and sensitivity analyses supported the main findings
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study. Semin Arthritis Rheum. Published 21 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →